{"name":"Suneet Agarwal","slug":"suneet-agarwal","ticker":"","exchange":"","domain":"","description":"Suneet Agarwal is a biotechnology company focused on the development of novel therapies in the early stages of clinical research. The company currently has two drugs in Phase 1 trials, deoxycytidine and deoxythymidine, which are being evaluated for their potential therapeutic benefits.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-25","label":"deoxycytidine Phase 3 readout (Gastric Cancer)","drug":"deoxycytidine","drugSlug":"deoxycytidine","type":"phase3_readout","sentiment":"neutral"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"deoxycytidine Phase 3 readout (NMIBC)","drug":"deoxycytidine","drugSlug":"deoxycytidine","type":"phase3_readout","sentiment":"neutral"},{"date":"2030-10-01","label":"deoxycytidine Phase 3 readout (Non-muscle-invasive Bladder Cancer)","drug":"deoxycytidine","drugSlug":"deoxycytidine","type":"phase3_readout","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"deoxycytidine","genericName":"deoxycytidine","slug":"deoxycytidine","indication":"Other","status":"phase_1"},{"name":"deoxythymidine","genericName":"deoxythymidine","slug":"deoxythymidine","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"deoxycytidine","genericName":"deoxycytidine","slug":"deoxycytidine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"deoxythymidine","genericName":"deoxythymidine","slug":"deoxythymidine","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE15THhOQ0NvdExUdWdocTh4aVhZNGRsWktKd1pTVld5dFE5Z0pzMmRyTEFUck9JZktCMHotOUo1X3c4TzllZ21CMm9iQ2ZmeUdMNGJlclo5TEg0Qks3YkVNUF9DaVM?oc=5","date":"2021-10-29","type":"pipeline","source":"Harvard Medical School","summary":"Catalyzing New Treatments - Harvard Medical School","headline":"Catalyzing New Treatments","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}